AROMICS receives Horizon 2020 SME instrument funding to develop a new therapy for malignant mesothelioma

31/10/2018

BERMES, a proposal submitted by the Spanish biotechnology company AROMICS, has been selected to receive EU funding from H2020 SME Instrument Phase II topic. This grant represents the first big step forward for the company as it looks for bringing the first lead compound NAX035, closer to clinical application in cancer.

About SME Instrument at Horizon 2020 Research and Innovation Program

The SME Instrument is a EU funding scheme intended to support the SMEs' innovation activities.  Highly innovative SMEs with a clear commercial ambition and a potential for high growth and internationalisation are the prime target. Phase 2 of SME Instrument is focused on innovation and demonstration actions (prototyping, miniaturisation, scaling- up, design, performance verification, testing, development of pilot lines, etc.) and market replication. http://eshorizonte2020.es/

About AROMICS

Applied Research using Omic Sciences (AROMICS) is a biotechnology company founded in 2005 and located in the Barcelona Science Park.  AROMICS is a focused on the development of novel therapies therapies and diagnostic products targeting and effective management of relevant human health diseases like cancer. http://www.aromics.es